Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells
Open Access
- 13 July 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 130 (2), 176-180
- https://doi.org/10.1182/blood-2016-12-757377
Abstract
Langerhans cell histiocytosis (LCH) and the non-LCH neoplasm Erdheim-Chester disease (ECD) are heterogeneous neoplastic disorders marked by infiltration of pathologic macrophage-, dendritic cell–, or monocyte-derived cells in tissues driven by recurrent mutations activating MAPK signaling. Although recent data indicate that at least a proportion of LCH and ECD patients have detectable activating kinase mutations in circulating hematopoietic cells and bone marrow–based hematopoietic progenitors, functional evidence of the cell of origin of histiocytosis from actual patient materials has long been elusive. Here, we provide evidence for mutations in MAPK signaling intermediates in CD34+ cells from patients with ECD and LCH/ECD, including detection of shared origin of LCH and acute myelomonocytic leukemia driven by TET2-mutant CD34+ cell progenitors in one patient. We also demonstrate functional self-renewal capacity for CD34+ cells to drive the development of histiocytosis in xenotransplantation assays in vivo. These data indicate that the cell of origin of at least a proportion of patients with systemic histiocytoses resides in hematopoietic progenitor cells prior to committed monocyte/macrophage or dendritic cell differentiation and provide the first example of a patient-derived xenotransplantation model for a human histiocytic neoplasm.This publication has 26 references indexed in Scilit:
- High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosisBlood, 2014
- Femoral Bone Marrow Aspiration in Live MiceJournal of Visualized Experiments, 2014
- Somatic activating ARAF mutations in Langerhans cell histiocytosisBlood, 2014
- BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groupsThe Journal of Experimental Medicine, 2014
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutationBlood, 2013
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human LymphomagenesisCancer Cell, 2011
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3Leukemia, 2010
- Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans CellsThe Journal of Immunology, 2010